{"filings":[{"id":2409676,"accession_number":"0001193125-26-361105","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-08-21T20:10:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"MannKind files prospectus supplement for common stock issuance under shelf registration","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed prospectus supplement on Aug 21, 2026 to S-3 shelf (Reg. No. 333-285286) for common stock shares.","Cooley LLP legal opinion on share issuance legality filed as Exhibit 5.1.","No offering size, price, or use of proceeds disclosed in this 8-K.","Filing is procedural ahead of a potential stock sale; no financial figures provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2078678,"accession_number":"0001193125-26-335016","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-08-05T20:03:26+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q2 2026 revenue $109.4M (+43% YoY); Afrezza pediatric and Furoscix ReadyFlow approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $109.4M, up 43% YoY; Furoscix contributed $22.2M in net sales.","Afrezza net sales $17.0M (-7% YoY); pediatric indication approved May 29, early launch momentum.","Furoscix ReadyFlow autoinjector approved July 23; commercial launch expected late August.","Positive Phase 1b data for nintedanib DPI (MNKD-201) in IPF; global Phase 2 enrolling.","Closed $50M private placement to fund $45M CVR payment from Furoscix ReadyFlow approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1856639,"accession_number":"0001193125-26-316041","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-07-24T20:01:26+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"MannKind gets FDA approval for Furoscix ReadyFlow; raises $50M in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved Furoscix ReadyFlow (furosemide injection) for edema in adults with heart failure or chronic kidney disease.","Private placement of 10,440,838 shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, led by Frazier Life Sciences.","Gross proceeds ~$50M; net proceeds to fund $45M CVR payment triggered by FDA approval and for general corporate purposes.","Pre-funded warrants have $0.01 exercise price, no expiration, subject to 19.99% beneficial ownership limitation.","Company agreed to file resale registration statement within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787916,"accession_number":"0001193125-26-252544","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-06-02T12:00:36+00:00","items":["8.01"],"status":"ready","headline":"FDA approves Afrezza for pediatric diabetes patients ages 6+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved supplemental BLA for Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.","More than 350,000 U.S. children and adolescents live with diabetes; majority have type 1 and require lifelong insulin.","Approval fulfills the last postmarketing requirement from the original June 27, 2014 approval letter.","MannKind expects to expand the patient population for Afrezza beyond adults."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":705640,"accession_number":"0001193125-26-243074","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-05-28T12:37:11+00:00","items":["8.01"],"status":"ready","headline":"FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA informed MannKind on May 27, 2026 it is released from postmarketing requirement to assess pulmonary malignancy risk in 8,000-10,000 patients.","Only remaining postmarketing requirement for Afrezza is pediatric safety/efficacy; sBLA for ages 4-17 has PDUFA target action date May 29, 2026.","INHALE-1st study for youth (10-17) with type 1 diabetes activated eight additional sites; expects up to 100 participants across 10 sites.","Primary endpoint of INHALE-1st: percentage with CGM time in range ≥70% at 13 weeks; data expected late 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":611876,"accession_number":"0001193125-26-237183","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-05-22T21:17:49+00:00","items":["5.07"],"status":"ready","headline":"MannKind shareholders elect all 9 director nominees, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine board nominees elected; votes for ranged from 140.1M (Consiglio) to 143.5M (Binder), with 78.5M broker non-votes.","Advisory vote on executive compensation approved: 137.3M for, 16.3M against, 1.3M abstentions, 78.5M broker non-votes.","Ratification of Deloitte & Touche as auditor for FY 2026 passed: 221.1M for, 8.8M against, 3.6M abstentions, 0 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99591,"accession_number":"0001193125-26-208910","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q1 total revenue $90.2M (+15% YoY); Furoscix adds $15.5M; cash $134M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $90.2M (+15% YoY); royalties from Tyvaso DPI up 9% to $32.7M.","Furoscix net sales $15.5M (first full Q1 post-scPharma acquisition); Afrezza $15.3M (+3%).","SG&A surged 116% to $54.1M driven by launch prep for Afrezza pediatric and Furoscix ReadyFlow.","Cash and investments $134M; settled $36.3M convertible notes for $35.5M cash + 569K shares.","Key PDUFA dates: Afrezza pediatric May 29; Furoscix Autoinjector July 26; nintedanib DPI Phase 2 enrollment Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":90171000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115687,"accession_number":"0001193125-26-073509","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q4 revenue $112M (+46% YoY); Furoscix adds $23M in first quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $112M in Q4 2025, up 46% vs Q4 2024; full-year revenues $349M, up 22%.","Afrezza net sales $23M in Q4, +25% YoY; Furoscix net sales $23M since acquisition Oct 7, 2025.","PDUFA target dates: Afrezza pediatric sBLA May 29, 2026; Furoscix ReadyFlow sNDA July 26, 2026.","R&D expense $27.6M (+148% YoY); SG&A $58.4M (+144%) driven by Furoscix and launch prep.","Cash & investments $176M at Dec 31, 2025; scPharmaceuticals acquisition completed Oct 7."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":348966000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132121,"accession_number":"0001193125-25-319170","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K/A","filed_at":"2025-12-15T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"MannKind pro forma shows $36.1M net loss for H1 2025 post-scPharma acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired scPharma for $5.35/share cash plus CVR (up to $1.00/share); total consideration $396.4M cash.","Pro forma combined net loss of $36.1M for six months ended June 30, 2025 vs. MannKind standalone net income of $13.8M.","Pro forma combined net loss of $96.9M for year ended Dec 31, 2024 (MannKind $27.6M income, scPharma $85.1M loss).","Acquisition financed via $325M term loan (initial $75M, DDTL $75M, incremental $175M) at SOFR + 4.75% margin.","Pro forma total assets $765.8M, total liabilities $832.6M, stockholders' deficit $66.8M as of June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132124,"accession_number":"0001193125-25-273321","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MannKind discontinues Phase 3 MNKD-101 trial for NTM lung disease after futility analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinuation based on interim analysis of first 46 participants; none showed sputum culture conversion.","DSMB agreed with decision due to futility; no safety issues identified in any DSMB meetings.","Company will investigate outcome and focus on advancing MNKD-102 dry powder formulation toward Phase 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132123,"accession_number":"0001193125-25-265810","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q3 revenue $82.1M (+17% YoY); completes scPharma acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenues $82.1M (+17% YoY); YTD revenues $237.0M (+14%).","GAAP net income $8.0M ($0.03 EPS) vs $11.6M in Q3 2024; non-GAAP net income $22.4M ($0.07) +45%.","Completed scPharmaceuticals acquisition Oct 7 with ~$133.2M cash & $250M in delayed draw term loans.","Afrezza pediatric sBLA accepted (PDUFA May 29, 2026); FUROSCIX sNDA submitted; MNKD-101 & MNKD-201 trials advancing.","Appointed Dr. Ajay Ahuja as CMO; cash & investments $286.3M at Sep 30."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":237011000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132122,"accession_number":"0001193125-25-236064","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["1.01","2.01","2.03","9.01"],"status":"ready","headline":"MannKind completes $296.5M acquisition of scPharmaceuticals; funds with $250M debt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer expired Oct 6 with 73.47% shares tendered; merger closed Oct 7, 2025; scPharma becomes wholly owned subsidiary.","scPharma shareholders received $5.35 cash plus one CVR per share; CVR pays up to $1.00 additional contingent on milestones.","Aggregate cash paid ~$296.5M for shares; extinguished ~$82.6M scPharma debt (Perceptive credit and revenue participation).","Funded via $250M delayed draw term loan under amended Blackstone credit facility; interest SOFR+4.75%, matures Aug 2030.","CVR Milestone 1: FDA approval of SCP-111 autoinjector by June 2027 ($0.25-$0.75); Milestone 2: net sales $110M-$120M by Dec 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148693,"accession_number":"0000950170-25-111586","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MannKind receives $5M upfront from United Therapeutics for new product option exercise","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["MannKind entered First Amendment with United Therapeutics to exercise option for an additional development product using its Technosphere platform.","MannKind receives $5M upfront payment and is eligible for up to $35M in milestone payments.","MannKind will manufacture clinical trial materials; United Therapeutics will conduct all other preclinical and clinical development.","MannKind will earn 10% royalties on net sales of the additional product if approved.","United Therapeutics exercised withdrawal option retains right to withdraw the exercise for the new agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148692,"accession_number":"0001193125-25-186994","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"MannKind to acquire scPharmaceuticals for $5.35/share plus CVR up to $1.00/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Offer price: $5.35 cash + one contingent value right (CVR) per share; CVR milestones up to $1.00 aggregate.","CVR milestones: FDA approval of SCP-111 injection by June 30, 2027 (Milestone 1) and $110M+ net sales of specified products by Dec 31, 2026 (Milestone 2).","Principal stockholders holding ~11.5% of SCPH shares have agreed to tender and support the deal.","MannKind obtained $175M incremental delayed draw term loan from Blackstone to finance transaction costs; will repay ~$81M of SCPH's Perceptive debt upon close.","Strategic rationale: acquisition of FUROSCIX (approved for heart failure and chronic kidney disease) to expand into cardiorenal medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148691,"accession_number":"0000950170-25-103532","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q2 revenue $76.5M (+6% YoY); Afrezza sBLA for pediatric population submitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $76.5M, up 6% YoY; net income $0.7M versus net loss $2.0M in Q2 2024.","Afrezza sales $18.3M (+13% YoY); royalties from Tyvaso DPI $31.2M (+22%).","Non-GAAP net income $13.9M ($0.05/share) vs $14.3M ($0.05) in Q2 2024.","Submitted sBLA for Afrezza in pediatric patients (ages 4-17); FDA decision expected early Q4 2025.","ICoN-1 trial of MNKD-101 enrollment ahead of schedule; interim target of 100 patients expected early Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":154881000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167567,"accession_number":"0000950170-25-074523","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MannKind stockholders elect all 9 directors, approve say-on-pay, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected 9 directors (including James S. Shannon, Michael E. Castagna) with between 133.7M and 137.8M votes for each.","Advisory vote on named executive officer compensation approved: 131.4M for, 11.5M against.","Ratified Deloitte & Touche as auditor for FY2025: 211.7M for, 5.3M against, no broker non-votes.","Broker non-votes were 75.7M on director elections and say-on-pay, but 0 on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167566,"accession_number":"0001193125-25-120797","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MannKind Chief Medical Officer Burkhard Blank to depart; separation terms include $386K bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Burkhard Blank stepped down as CMO and EVP R&D effective May 9, 2025, becoming non-executive employee.","Last day of employment is August 1, 2025; base salary continued for 13 weeks through Oct 31, 2025.","One-time special bonus of $386,000 payable in January 2026; COBRA premiums reimbursed until Oct 31.","Equity awards continue to vest while Blank remains employed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167565,"accession_number":"0000950170-25-066426","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q1 revenue $78M (+18% YoY); net income $13.2M (+24%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["1Q25 revenue $78.4M (+18% YoY); GAAP net income $13.2M (+24%); non-GAAP net income $21.6M (+43%).","Royalty revenue $30M (+32%) from increased Tyvaso DPI demand; collaborations & services $29.4M (+18%) from United Therapeutics.","Afrezza NRx grew 20% YoY; sBLA for pediatric approval expected mid-2025.","MNKD-101 Phase 3 ICON-1: 55 patients randomized, 85% sites activated; target 100 patients by YE 2025.","Cash & investments $198M; MNKD-201 (nintedanib DPI) expected to advance to next phase in 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":78354000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184854,"accession_number":"0000950170-25-027721","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind reports 2024 revenue of $286M, net income of $28M; debt reduced by $236M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 revenue $286M (+43% YoY); Q4 revenue $77M (+31% YoY).","GAAP net income $27.6M ($0.10 EPS basic) vs loss of $11.9M in 2023; non-GAAP net income $67.7M ($0.25 EPS).","Reduced debt principal by $236M, remaining $36M convertible notes; year-end cash $203M.","Afrezza INHALE-1 pediatric trial met primary endpoint; FDA meeting planned 1H 2025 for potential sNDA.","MNKD-101 Phase 3 interim enrollment target expected by YE 2025; MNKD-201 Phase 1 completed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":285504000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184853,"accession_number":"0000950170-25-002291","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lauren Sabella to retire from MannKind July 18, 2025; appointed EVP, Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lauren Sabella notified retirement effective July 18, 2025.","Board appointed Sabella as Executive Vice President, Operations effective January 6, 2025.","Sabella remains on executive leadership team until retirement but will no longer oversee Endocrine Business Unit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201447,"accession_number":"0001193125-24-280821","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"MannKind exchanges $193.7M of 2.50% convertible notes for 26.7M shares plus $89.2M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal $193.7M of 2.50% Convertible Senior Notes due 2026 exchanged for 26,749,559 shares of common stock.","Cash payment of ~$89.2M additional exchange consideration.","Closings expected on Dec. 20 and Dec. 23, 2024, subject to conditions.","After exchange, ~$36.3M principal of Notes remains outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201446,"accession_number":"0000950170-24-123273","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q3 total revenue $70M (+37% YoY); YTD net income $20M, non-GAAP $45M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $70.1M (+37% YoY); YTD revenue $208.7M (+49% YoY); YTD net income $20M.","Tyvaso DPI royalties up 34% to $27.1M (Q3) and 48% YTD to $75.3M; collaboration revenue +78% on manufacturing.","Afrezza net revenue up 12% to $15.0M (Q3); V-Go net revenue up 5% to $4.7M.","Pipeline: MNKD-101 Phase 3 global expansion; MNKD-201 Phase 1 complete, FDA meeting 1H 2025; INHALE-3 positive; pediatric data due Q4.","Cash and investments $268.4M; $5.3M bargain purchase gain from Pulmatrix deal."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":208728000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217450,"accession_number":"0001193125-24-200252","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kent Kresa to retire from MannKind Board; Steven B. Binder appointed effective Sept 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kent Kresa notified MannKind board of his retirement on Aug 13, effective Sept 30, 2024.","Board approved appointment of Steven B. Binder as director, effective on Kresa's retirement date.","Binder currently serves as EVP, Special Projects; his employment will end concurrently with board appointment.","Binder will be eligible for non-employee director compensation as described in prior SEC filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217449,"accession_number":"0000950170-24-092289","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q2 revenue $72M (+49% YoY), net income $9M YTD; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenues $72.4M, up 49% vs. $48.6M in Q2 2023; YTD revenues $138.6M, up 55%.","YTD 2024 net income of $9M; non-GAAP net income $29M; cash & investments $261.9M.","Tyvaso DPI royalties up 34% to $25.6M; collaborations and services revenue up 132% to $26.0M.","Afrezza net revenue $16.3M (+20%); V-Go net revenue $4.5M (-7%).","Pipeline: MNKD-101 Phase 3 initiated; MNKD-201 Phase 1 on track for 4Q 2024 readout."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":138649000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237317,"accession_number":"0000950170-24-061164","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MannKind shareholders elect all nine directors, approve say-on-pay, ratify Deloitte","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Nine director nominees elected; highest votes 120.0M for Sabrina Kay, lowest 118.5M for Ronald Consiglio.","Advisory vote on executive compensation approved: 112.3M for, 11.6M against, 72.3M broker non-votes.","Ratification of Deloitte & Touche as auditor passed: 191.8M for, 3.8M against, 0 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237316,"accession_number":"0000950170-24-055622","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q1 revenue $66M (+63% YoY); net income $11M; FDA Fast Track for MNKD-101","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $66.3M (+63% YoY); GAAP net income $11M; non-GAAP net income $15M.","Tyvaso DPI royalties surged 94% to $22.7M; collaborations & services revenue up 118% to $24.8M.","Afrezza net revenue $14.4M (+16%); V-Go down 16% to $4.3M.","Cash and investments $304.5M; repaid ~$37M of secured debt in early April.","FDA Fast Track and IND clearance for MNKD-101 (clofazimine inhaled suspension)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":66263000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237315,"accession_number":"0000950170-24-041225","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MannKind repays ~$31.6M MidCap debt, terminates $8.9M convertible note with Mann Group","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Apr 1, 2024, repaid ~$31.6M under MidCap Loan Agreement (incl. $2.8M exit fee, $0.3M prepayment fee); all liens released.","On Apr 2, 2024, terminated Convertible Note to Mann Group: issued 1.5M shares and paid ~$8.9M cash to extinguish ~$8.9M principal+interest.","Note was convertible into 3,554,198 shares; termination removes that potential dilution from equity.","Total debt eliminated includes ~$31.6M MidCap loan and ~$8.9M Mann Group Note; Loan Agreement maturity was Aug 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254856,"accession_number":"0001193125-24-077611","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MannKind appoints Chris Prentiss as CFO; Steven Binder retires as CFO but stays as EVP Special Projects","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Steven Binder retiring effective April 22, 2024; will serve as EVP Special Projects through Dec 31, 2024.","Christopher Prentiss appointed CFO, effective April 22, 2024; previously CFO at ADARx Pharmaceuticals.","Prentiss receives $460,000 base salary, 50% target bonus, 103,600 RSUs (4-year vest), and EVP equity grant in May 2024.","Prentiss eligible for relocation assistance and change of control agreement with severance and tax gross-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254855,"accession_number":"0000950170-24-021095","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind FY 2023 revenue doubled to $199M; Q4 posts GAAP net income of $1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2023 total revenues $199M, +99% YoY; Q4 revenues $58M, +62% YoY.","Q4 2023 net income of $1M (GAAP); Non-GAAP net income of $7M.","Afrezza Q4 net revenue $15.5M (+29%); Tyvaso DPI royalties Q4 $21.0M (+132%).","Cash $302.3M at year-end; plans Phase 3 for MNKD-101 and Phase 1 for MNKD-201 in H1 2024.","Commercial product gross margin 70% in Q4 vs 77% prior year; lower due to cost timing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":198962000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254854,"accession_number":"0001193125-24-000161","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MannKind sells 1% Tyvaso DPI royalty to Sagard for $150M upfront, retains 9%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sagard pays MannKind $150M upfront for a 1% royalty on global net sales of Tyvaso DPI through Dec 31, 2042.","MannKind retains a 9% royalty on Tyvaso DPI; total 10% royalty pool split 1% Sagard / 9% MannKind.","Milestone: $50M if trailing 12-month net sales hit $1.9B by Dec 31, 2026; else $45M if $2.3B by Sep 30, 2027.","If milestones not met, no milestone payment and Sagard forgoes royalty on net sales above $3.5B in any calendar year.","Transaction closed Dec 27, 2023; proceeds net of legal expenses; customary representations and indemnities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272339,"accession_number":"0001193125-23-303995","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MannKind restructures Amphastar supply deal: lowers annual commitments, adds capacity fees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prior total purchase commitments of €58.7M for 2024-27 replaced; new commitments for 2024 = €2.9M, 2025 = €1.5M.","Capacity fee introduced: €2M/year in Year 1 of new supply, decreasing to €500k/year in Years 6-9.","Term extended to later of Dec 31, 2035 or completion of purchase commitments.","Amendment accommodates change in source of inclusion bodies (insulin intermediate) to Amphastar-manufactured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272338,"accession_number":"0000950170-23-060230","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q3 total revenue $51M, up 56% YoY; net income $2M GAAP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $51.3M, +56% YoY; net income $2M (GAAP); non-GAAP net income $4M.","Tyvaso DPI royalties $20.2M, +225% YoY, driven by patient demand.","Afrezza net revenue $13.5M, +24% YoY on higher demand and price; V-Go down 18%.","Cash and investments $144.3M; R&D spending rose to $10M (vs $4.1M) on pipeline MNKD-101.","Commercial product gross margin improved to 78% from 69% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":140490000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289176,"accession_number":"0000950170-23-039048","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q2 total revenues $49M (+157% YoY); Tyvaso DPI royalties $19M (+63% QoQ)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Tyvaso DPI royalties $19M in Q2, up 63% from Q1, driven by strong patient demand.","Afrezza net revenue $13.5M, up 27% YoY due to higher demand and price.","GAAP income from operations $2M; non-GAAP income from operations $8M.","Total revenues H1 2023 $89.2M, +189% vs H1 2022.","Cash and investments $146.6M as of June 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":89237000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289175,"accession_number":"0000950170-23-031202","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MannKind: fire at contract manufacturer delays MNKD-101 clinical supply by 3-6 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fire at contract manufacturer's German facility producing clofazimine inhalation solution (MNKD-101).","Production of clinical supplies delayed by 3-6 months.","Planned Phase 2/3 clinical study initiation for later 2023 may be impacted.","Company evaluating mitigation strategies; will update timing projections later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309941,"accession_number":"0001193125-23-156575","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"MannKind shareholders approve doubling authorized common stock to 800M shares and adding 25M shares to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock doubled to 800M shares via Charter Amendment filed with Delaware.","2018 Equity Incentive Plan increased by 25M shares; ESPP increased by 3M shares.","All nine director nominees elected; say-on-pay approved; Deloitte ratified as auditor.","Advisory vote favored annual frequency for say-on-pay; company will continue annual votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309939,"accession_number":"0000950170-23-019977","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K/A","filed_at":"2023-05-10T23:59:59+00:00","items":["9.01","2.02"],"status":"ready","headline":"MannKind Q1 2023 revenues jump 239% to $41M; loss from ops down 72%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $40.6M, +239% vs Q1 2022; Tyvaso DPI contributed $23M (services + royalties).","Afrezza net revenue $12.4M (+26% YoY); V-Go added $5.1M after Q2 2022 acquisition.","Loss from operations narrowed 72% to $6M; commercial product gross margin 69%.","Cash and investments $166.6M at March 31, 2023; R&D spend up to $5.6M for pipeline.","CEO cites strong Tyvaso DPI demand; Phase 2/3 inhaled clofazimine trial planned H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":40626000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309940,"accession_number":"0000950170-23-019629","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q1 2023 total revenues $40.6M (+239% YoY); Tyvaso DPI drives $23M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $40.6M vs $12.0M in Q1 2022, a 239% increase.","Tyvaso DPI contributed $23M in revenue (collaborations/services $11.4M, royalties $11.7M).","Afrezza net revenue $12.4M (+26% YoY); V-Go added $5.1M (acquired mid-2022).","Loss from operations improved 72% to $6M; cash and investments $166.6M at March 31.","CEO cites strong Tyvaso DPI demand; Phase 2/3 inhaled clofazimine trial to start H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":40626000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328637,"accession_number":"0001193125-23-080473","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MannKind appoints Lauren Sabella as EVP, Chief Operating Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective March 27, 2023; reports to CEO Michael Castagna.","Annual base salary $440,000; target bonus 50% of base salary.","Equity award of 210,000 RSUs vesting 25% annually over four years.","Sabella previously COO at Acorda Therapeutics; 18-year career at Boehringer Ingelheim.","Change of control agreement provides severance and accelerated vesting under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328636,"accession_number":"0001564590-23-002306","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind reports 2022 total revenues of $100M, up 32% YoY; Tyvaso DPI royalties $16M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 total revenues $36.1M (+188% YoY); full-year $99.8M (+32% vs 2021).","Afrezza net revenue $43.3M in 2022 (+11%); V-Go contributed $12.9M after Q2 acquisition.","Tyvaso DPI royalties $15.6M in 2022 ($9.1M in Q4); $37.9M manufacturing revenue deferred.","Cash and investments $172.8M at Dec 31, 2022; INHALE-1 pediatric trial 50% enrolled.","Inhaled clofazimine (MNKD-101) to enter adaptive Phase 2/3 study in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":99770000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346307,"accession_number":"0001564590-22-036932","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q3 2022 revenue $32.8M, up 48% YoY; net loss widens to $14.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $32.8M (+48% YoY); Afrezza net revenue $10.8M (+11%), V-Go net revenue $5.4M.","Tyvaso DPI royalties $6.2M; collaborations and services $10.3M including manufacturing revenue.","Net loss $14.4M ($0.06/sh) vs $4.4M loss in Q3 2021; higher SG&A and interest expense.","Afrezza gross margin 81% (up from 61%); V-Go gross margin 46%.","Cash and investments $177.8M; nine-month net loss $69.5M ($0.27/sh)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":63711000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346306,"accession_number":"0001564590-22-035783","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MannKind CTO Joseph Kocinsky steps down from role effective Oct 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Kocinsky's duties as Chief Technology Officer reduced; no longer functions in that position.","Kocinsky remains employed at-will with MannKind after effective date.","No successor named; transition effective October 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362701,"accession_number":"0001564590-22-032286","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2022-09-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"EVP Endocrine Business Unit Alejandro Galindo resigns effective Oct 21, 2022","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Alejandro Galindo, Executive Vice President – Endocrine Business Unit, resigns to pursue other opportunity.","Resignation effective at close of business on October 21, 2022.","No replacement named or additional details provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362700,"accession_number":"0001564590-22-028748","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q2 2022 revenue $18.9M, net loss narrows to $29.0M; Tyvaso DPI approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial product net revenue $12.7M (Afrezza $10.6M, V-Go $2.1M), up 28% YoY; collaboration $5.9M.","Net loss $29.0M ($0.11/sh) vs $35.5M ($0.14/sh) in Q2 2021; narrowed due to prior-year debt extinguishment loss.","Tyvaso DPI (pulmonary hypertension) FDA approved May 2022; first manufacturing & royalty revenue from United Therapeutics recognized in Q2.","V-Go insulin patch acquisition May 31 generated $2.1M net revenue in June; gross profit $0.8M.","Afrezza gross margin improved to 68% from 56% on higher sales and lower COGS."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":30886000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382281,"accession_number":"0001564590-22-021266","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2022-05-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Tyvaso DPI using MannKind's Technosphere platform; availability June 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tyvaso DPI is second FDA-approved product using MannKind's Technosphere inhalation platform; first dry powder inhaled treatment for PAH and PH-ILD.","Manufacturing of Tyvaso DPI underway at MannKind's Connecticut facility; product availability expected in June 2022.","Commercial supply agreement with United Therapeutics runs through 2031; initially signed in August 2021.","Tyvaso DPI uses dry powder formulation and Dreamboat inhaler technology from Afrezza; convenient alternative to liquid nebulization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382280,"accession_number":"0001193125-22-157444","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["2.03","8.01"],"status":"ready","headline":"MannKind to acquire V-Go device from Zealand Pharma for $10M plus up to $17M in inventory and milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price: $10.0M plus book value of finished goods inventory (not to exceed $7.0M) and up to $10.0M in sales-based milestone payments.","Milestone payments triggered when annual V-Go revenue reaches thresholds between $40M and $100M.","Company will assume a facility lease in Marlborough, MA with monthly payments of $28,895, expiring Feb 2026.","Up to 40 current and former Zealand employees to be offered positions, including field sales and supply chain roles.","Closing expected in May 2022 subject to satisfaction of customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382279,"accession_number":"0001564590-22-019928","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MannKind stockholders elect all nine director nominees at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; each received >82.8M votes for, with >87.5M broker non-votes.","Advisory say-on-pay approved with 78,653,564 votes for, 9,041,501 against, 1,224,148 abstentions.","Ratification of Deloitte & Touche as independent auditor for FY2022 passed with 172,202,911 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382278,"accession_number":"0001564590-22-018297","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q1: Afrezza net revenue $9.8M (+21% YoY); net loss $26.0M; cash $233M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Afrezza net revenue $9.8M, up 21% vs Q1 2021; gross margin improved to 77% from 47%.","Net loss $26.0M ($0.10 per share) vs $12.9M ($0.05) in Q1 2021, driven by lower collaboration revenue.","Cash and investments $233.0M at March 31, 2022; Tyvaso DPI PDUFA action date expected May 2022.","Collaborations & services revenue $2.2M, down $7.2M due to completion of R&D services for United Therapeutics.","Deferred revenue from commercial supply agreement with United Therapeutics increased to $25.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":11992000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400214,"accession_number":"0001564590-22-006688","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind reports 2021 revenue $75.4M, +16%; Afrezza Q4 record $11.3M; net loss widens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues 2021: $75.4M (+16% vs 2020); Afrezza net revenue $39.2M (+21% YoY)","Q4 Afrezza net revenue $11.3M (+13% vs Q4 2020); collaborations revenue $1.2M","Cash and investments $260.7M at Dec 31, 2021 vs $67.2M a year ago; includes $230M convertible note and ~$100M sale-leaseback","Full-year net loss $80.9M ($0.32/sh) vs $57.2M ($0.26/sh) in 2020; non-GAAP loss $61.7M ($0.25/sh)","Tyvaso DPI PDUFA deadline extended to May 2022; clofazimine Phase 1 trial commenced in 1Q 2022"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":75442000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400213,"accession_number":"0001564590-22-001402","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2022-01-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MannKind partner UT's Tyvaso DPI NDA accepted for FDA Class 1 review; goal Feb 2022","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted United Therapeutics' resubmitted NDA for Tyvaso DPI as a Class 1 response.","User fee goal date set for February 2022.","UT previously received a Complete Response Letter in October 2021 for the NDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419189,"accession_number":"0001564590-21-061212","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2021-12-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"United Therapeutics resubmits Tyvaso DPI NDA to FDA after CRL","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["UT received a Complete Response Letter from FDA on Oct 18, 2021 for Tyvaso DPI.","UT disclosed on Dec 27, 2021 that it has resubmitted the NDA to FDA.","Tyvaso DPI uses MannKind's Inhalation technology; resubmission is a key regulatory milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-12-27T23:59:59+00:00|419189"}